BeiGene (BGNE)

Quick facts

Marketed products

• Brukinsa · Oncology · revenue 2700
  Brukinsa blocks the BTK protein, which is involved in the activation of B cells.
• Tevimbra · Oncology · revenue 900
  Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells.
• TEVIMBRA · Other
• Brukinsa

Phase 3 pipeline

• BGB-15025 · Oncology
  BGB-15025 is a selective inhibitor of menin that disrupts the interaction between menin and mixed-lineage leukemia (MLL) proteins, restoring normal gene expression in acute leukemias.
• BGB-A445 · Oncology
  BGB-A445 is a Bcl-2 inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.
• LBL-007 · Oncology
  LBL-007 is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell and myeloid cell activation in hematologic malignancies.
• Pamiparib capsule · Oncology
  Pamiparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair and causing cancer cell death.

Phase 2 pipeline

• BGB-11417
• BGB-290 · Oncology
  PARP inhibitor
• BGB-45035
• BGB-A425
• BGB-DXP593 · Oncology
  BGB-DXP593 is a small molecule inhibitor targeting the CD73 enzyme.
• Chemotherapy Doublet · Oncology
  Chemotherapy agents work by interfering with DNA replication and cell division, leading to cell death.
• Concurrent Chemoradiotherapy

Phase 1 pipeline

• [14C]-BGB-11417
• [14C]-BGB-16673
• [14C]-BGB-3111
• [14C]-pamiparib
• Bevacizumab or Bevacizumab biosimilar
• BG-60366
• BG-68501
• BGB-10188
• BGB-283
• BGB-3111 and Drug Cocktail
• BGB-53038
• BGB-B455
• BGB-C354
• BGB-DXP604
• Drug: BG-T187
• Histology-Based Chemotherapy Doublet
• Other Therapeutic Agents
• Tislelizumab IV
• Tislelizumab SC

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BeiGene portfolio CI brief
• BeiGene pipeline updates RSS